In this application, we propose to establish an integrated proteome characterization center (PCC) with an outstanding team of scientists and clinicians in order to construct a cancer biomarker pipeline using genoproteomic approaches. This multidisciplinary team consists of internationally recognized experts in clinical oncology, clinical chemistry, cancer biology, proteomic technologies, proteomics/genomics-specific bioinformatics, biostatistics and experimental design, metrology/standards, technology optimization, assay construction, project management and patient advocacy. The plan is to connect genomics with proteomics (genoproteomics). We believe that genomic data provides a highly valuable molecular route towards the identification of genes and pathways that could be useful for the detection, differential diagnosis, outcome prediction and therapeutic targets of cancer. The proteomic approaches will provide the identification of unique features that are inherent to proteins including post-translational modifications, such as glycosylation and phosphorylation. We propose a two- step strategy to construct an evidence-based, proteomic biomarker pipeline for ovarian and other carcinomas. The first step is the discovery of candidate biomarkers from genomic data including TCGA using mass spectrometry and affinity based technologies on human specimens. The goal is to comprehensively characterize tumor and normal biospecimens and identify their protein composition in order to systematically identify and prioritize cancer-related proteins for advancement to verification. The second step is the verification of these candidates using targeted assays. The goal is to generate accurate, reproducible, sensitive, quantitative, multiplex assays using optimized and standardized high-throughput technologies for the discovered biomarkers. While this application is not intended to conduct large scale clinical studies, we believe that the ultimate clinical application and the performance characteristics of these assays should be clearly defined. With this multidisciplinary team of outstanding scientists and clinicians, our PCC offers the best opportunity for the success of biomarker discovery and verification for personalized cancer medicine.

Public Health Relevance

Understanding the molecular networking in carcinogenesis is essential for the development of a successful strategy to reduce cancer mortality. Based on the genomic alterations identified from TCGA and other sources, this application will focus on the development of a clinically useful protein biomarker pipeline using state-of-the art proteomics technologies for personalized cancer medicine.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
5U24CA160036-04
Application #
8764711
Study Section
Special Emphasis Panel (ZCA1-SRLB-R (J1))
Program Officer
Hiltke, Tara
Project Start
2011-08-29
Project End
2016-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
4
Fiscal Year
2014
Total Cost
$1,890,981
Indirect Cost
$515,090
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Menon, Rajasree; Im, Hogune; Zhang, Emma Yue et al. (2014) Distinct splice variants and pathway enrichment in the cell-line models of aggressive human breast cancer subtypes. J Proteome Res 13:212-27
Wu, Xinyan; Renuse, Santosh; Sahasrabuddhe, Nandini A et al. (2014) Activation of diverse signalling pathways by oncogenic PIK3CA mutations. Nat Commun 5:4961
Aiyetan, Paul; Zhang, Bai; Chen, Lily et al. (2014) M2Lite: An Open-source, Light-weight, Pluggable and Fast Proteome Discoverer MSF to mzIdentML Tool. J Bioinform 1:40-49
Harlan, Robert; Zhang, Hui (2014) Targeted proteomics: a bridge between discovery and validation. Expert Rev Proteomics 11:657-61
Kim, Min-Sik; Zhong, Yi; Yachida, Shinichi et al. (2014) Heterogeneity of pancreatic cancer metastases in a single patient revealed by quantitative proteomics. Mol Cell Proteomics 13:2803-11
Liu, Yansheng; Chen, Jing; Sethi, Atul et al. (2014) Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness. Mol Cell Proteomics 13:1753-68
Tang, Shuang; Huang, Gang; Fan, Wei et al. (2014) SIRT1-mediated deacetylation of CRABPII regulates cellular retinoic acid signaling and modulates embryonic stem cell differentiation. Mol Cell 55:843-55
Sun, Shisheng; Zhou, Jian-Ying; Yang, Weiming et al. (2014) Inhibition of protein carbamylation in urea solution using ammonium-containing buffers. Anal Biochem 446:76-81
Yang, Shuang; Zhang, Hui (2014) Glycomic analysis of glycans released from glycoproteins using chemical immobilization and mass spectrometry. Curr Protoc Chem Biol 6:191-208
Yang, Weiming; Laeyendecker, Oliver; Wendel, Sarah K et al. (2014) Glycoproteomic study reveals altered plasma proteins associated with HIV elite suppressors. Theranostics 4:1153-63

Showing the most recent 10 out of 45 publications